Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Calliditas Therapeutics

CALT
Current price
40.03 USD -0.43 USD (-1.06%)
Last closed 39.99 USD
ISIN US13124Q1067
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 080 668 032 USD
Yield for 12 month +147.10 %
1Y
3Y
5Y
10Y
15Y
CALT
21.11.2021 - 28.11.2021

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. Address: Kungsbron 1, D5, Stockholm, Sweden, 111 22

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

39.2 USD

P/E ratio

Dividend Yield

Current Year

+118 509 109 USD

Last Year

+78 837 867 USD

Current Quarter

+54 967 014 USD

Last Quarter

+29 014 449 USD

Current Year

+110 942 578 USD

Last Year

+77 345 220 USD

Current Quarter

+49 718 743 USD

Last Quarter

+27 638 555 USD

Key Figures CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -365 368 992 USD
Operating Margin TTM -5.63 %
PE Ratio
Return On Assets TTM -13.41 %
PEG Ratio
Return On Equity TTM -157.2 %
Wall Street Target Price 39.2 USD
Revenue TTM 1 601 414 016 USD
Book Value 1.98 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 107.8 %
Dividend Yield
Gross Profit TTM 787 678 000 USD
Earnings per share -1.72 USD
Diluted Eps TTM -1.72 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -30 %

Dividend Analytics CALT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 22.4719
Enterprise Value Revenue 7.0892
Price Sales TTM 0.6748
Enterprise Value EBITDA -0.8043
Price Book MRQ 105.1765

Financials CALT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CALT

For 52 weeks

15.25 USD 42.1 USD
50 Day MA 39.4 USD
Shares Short Prior Month 8 873
200 Day MA 28.26 USD
Short Ratio 0.3
Shares Short 3 493
Short Percent 0.02 %